Profile data is unavailable for this security.
About the company
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
- Revenue in USD (TTM)2.61bn
- Net income in USD-175.01m
- Incorporated1995
- Employees6.50k
- LocationExact Sciences Corp5505 Endeavor LaneMADISON 53719United StatesUSA
- Phone+1 (608) 284-5700
- Fax+1 (608) 284-5701
- Websitehttps://www.exactsciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | 742.00k | -519.21m | 7.71bn | 443.00 | -- | 4.73 | -- | 10,396.04 | -3.65 | -3.65 | 0.0051 | 9.77 | 0.0005 | -- | 0.5912 | 1,962.96 | -36.03 | -29.76 | -38.48 | -32.59 | -- | -- | -69,973.99 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Tempus AI Inc | 595.57m | -790.20m | 7.73bn | 2.30k | -- | 78.67 | -- | 12.98 | -8.23 | -8.23 | 4.34 | 0.6367 | -- | -- | -- | -- | -- | -- | -- | -- | 51.85 | -- | -121.04 | -- | 3.52 | -28.75 | 0.8183 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 455.99m | -285.01m | 9.31bn | 2.20k | -- | 8.03 | -- | 20.42 | -1.57 | -1.57 | 2.51 | 6.33 | 0.2446 | 10.63 | 32.42 | 253,328.30 | -15.29 | -37.71 | -17.63 | -47.19 | 60.28 | -- | -62.50 | -286.51 | 4.78 | -16.63 | 0.2263 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.08bn | 431.79m | 10.82bn | 20.00k | 25.04 | 2.91 | 13.94 | 2.65 | 8.37 | 8.37 | 78.94 | 72.13 | 0.5188 | 8.23 | 5.22 | 203,888.80 | 5.67 | 6.46 | 6.52 | 7.62 | 35.98 | 36.99 | 10.93 | 11.58 | 1.21 | 4.97 | 0.39 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Medpace Holdings Inc | 2.03bn | 339.64m | 11.45bn | 5.80k | 34.71 | 14.95 | 31.11 | 5.64 | 10.63 | 10.63 | 63.59 | 24.69 | 1.22 | -- | 7.05 | 344,075.90 | 20.43 | 13.94 | 45.87 | 23.18 | 28.52 | 28.84 | 16.74 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.50bn | 47.30m | 12.12bn | 1.31k | 304.96 | 11.24 | 139.23 | 8.05 | 0.4168 | 0.4168 | 15.40 | 11.30 | 0.4595 | 0.4948 | 5.04 | 1,145,352.00 | 1.44 | -21.63 | 1.76 | -25.75 | 88.29 | 86.65 | 3.14 | -77.05 | 3.19 | -- | 0.5324 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Neurocrine Biosciences, Inc. | 2.12bn | 339.20m | 12.16bn | 1.50k | 36.37 | 4.84 | 33.43 | 5.74 | 3.31 | 3.31 | 20.64 | 24.87 | 0.7163 | 0.9811 | 4.95 | 1,513,929.00 | 11.46 | 9.77 | 13.74 | 12.19 | 98.28 | 98.51 | 16.00 | 14.79 | 4.08 | 6.10 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| BIO-TECHNE Corp | 1.16bn | 168.07m | 12.75bn | 3.10k | 76.79 | 6.15 | 45.56 | 11.00 | 1.05 | 1.05 | 7.20 | 13.08 | 0.4339 | 2.22 | 5.04 | 373,890.30 | 6.29 | 9.42 | 6.65 | 10.04 | 66.41 | 67.29 | 14.50 | 21.41 | 2.75 | 13.32 | 0.1336 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Insmed Inc | 328.61m | -802.69m | 12.88bn | 912.00 | -- | 321.89 | -- | 39.21 | -5.40 | -5.40 | 2.22 | 0.2329 | 0.2023 | 0.8789 | 9.22 | 360,312.50 | -49.41 | -40.96 | -63.68 | -46.88 | 77.61 | 77.99 | -244.27 | -212.92 | 2.53 | -14.67 | 0.9687 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Exact Sciences Corp | 2.61bn | -175.01m | 13.09bn | 6.50k | -- | 4.10 | 341.06 | 5.01 | -0.9607 | -0.9607 | 14.28 | 17.29 | 0.401 | 5.43 | 11.81 | 401,847.80 | -2.69 | -9.71 | -2.95 | -10.60 | 73.19 | 74.10 | -6.70 | -28.21 | 1.98 | -- | 0.4478 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Vaxcyte Inc | 0.00 | -497.19m | 15.56bn | 254.00 | -- | 6.52 | -- | -- | -4.62 | -4.62 | 0.00 | 17.96 | 0.00 | -- | -- | 0.00 | -27.70 | -34.22 | -28.85 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| United Therapeutics Corporation | 2.62bn | 1.07bn | 15.63bn | 1.17k | 16.15 | 2.74 | 13.83 | 5.97 | 21.75 | 21.75 | 53.16 | 128.25 | 0.3904 | 2.43 | 9.29 | 2,240,325.00 | 15.96 | 10.38 | 17.53 | 11.27 | 88.85 | 91.47 | 40.87 | 29.25 | 4.18 | -- | 0.0807 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Summit Therapeutics Inc | 0.00 | -161.69m | 16.78bn | 105.00 | -- | 85.99 | -- | -- | -0.2299 | -0.2299 | 0.00 | 0.2693 | 0.00 | -- | -- | 0.00 | -55.83 | -77.32 | -75.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -51.01 | 0.3389 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
Data as of Sep 19 2024. Currency figures normalised to Exact Sciences Corp's reporting currency: US Dollar USD
49.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 17.74m | 9.60% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 16.50m | 8.93% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 14.39m | 7.79% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 11.67m | 6.32% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 8.21m | 4.44% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 7.50m | 4.06% |
| William Blair Investment Management LLCas of 30 Jun 2024 | 4.33m | 2.34% |
| Holocene Advisors, LPas of 30 Jun 2024 | 4.04m | 2.19% |
| Artisan Partners LPas of 30 Jun 2024 | 3.81m | 2.06% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.10m | 1.68% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
